Setanaxib (GKT137831), a dual NOX1/NOX4 inhibitor, attenuated cardiac hypertrophy, fibrosis, inflammation and oxidative stress in TAC- [136], doxorubicin- [126], and isoproterenol- [98] induced heart failure models (Table 5). This evidence concerns the gene NOX4 and cardiac hypertrophy.